782.3000 -7.50 (-0.95%)
NSE Jun 06, 2025 15:31 PM
Volume: 430.4K
 

782.30
-0.95%
ICICI Securities Limited
Strides Pharma Science’s (Strides) Q3FY23 performance fell short of our revenue expectations, mainly due to negligible sales in the institutional business. Revenues grew 8.9% YoY (-3.6% QoQ) to Rs.8.7bn (I-Sec: Rs10bn).
Number of FII/FPI investors decreased from 283 to 268 in Mar 2025 qtr
More from Strides Pharma Science Ltd.
Recommended